再鼎医药:DLL3 ADC获FDA快速通道资格认定,用于治疗ES-SCLC

生物药大时代
21 May

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。近日,再鼎医药(纳斯达克股票代码:ZLAB;香港联交所股份代号:9688)宣布,FDA已授予具有同类首创潜力的Delta样配体3(DLL3)ADC ZL-1310快速通道资格认定,用于治疗广泛期小细胞肺癌(ES-SCLC)。目前ZL-1310正在开展全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10